184 related articles for article (PubMed ID: 34101105)
1. HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib.
Wehrenberg-Klee E; Sinevici N; Nesti S; Kalomeris T; Austin E; Larimer B; Mahmood U
Mol Imaging Biol; 2021 Dec; 23(6):930-940. PubMed ID: 34101105
[TBL] [Abstract][Full Text] [Related]
2. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
[TBL] [Abstract][Full Text] [Related]
3. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
[TBL] [Abstract][Full Text] [Related]
4. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).
Leary A; Evans A; Johnston SR; A'Hern R; Bliss JM; Sahoo R; Detre S; Haynes BP; Hills M; Harper-Wynne C; Bundred N; Coombes G; Smith I; Dowsett M
Clin Cancer Res; 2015 Jul; 21(13):2932-40. PubMed ID: 25398453
[TBL] [Abstract][Full Text] [Related]
6.
Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT
MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009
[TBL] [Abstract][Full Text] [Related]
7. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
Sato Y; Yashiro M; Takakura N
Cancer Sci; 2013 Dec; 104(12):1618-25. PubMed ID: 24112719
[TBL] [Abstract][Full Text] [Related]
8. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
9. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Garrett JT; Sutton CR; Kurupi R; Bialucha CU; Ettenberg SA; Collins SD; Sheng Q; Wallweber J; Defazio-Eli L; Arteaga CL
Cancer Res; 2013 Oct; 73(19):6013-23. PubMed ID: 23918797
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
11. AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib.
Buccinnà B; Ramondetti C; Piccinini M
Biochem Pharmacol; 2022 Oct; 204():115228. PubMed ID: 36007575
[TBL] [Abstract][Full Text] [Related]
12. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
13. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
14. Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.
Watson SS; Dane M; Chin K; Tatarova Z; Liu M; Liby T; Thompson W; Smith R; Nederlof M; Bucher E; Kilburn D; Whitman M; Sudar D; Mills GB; Heiser LM; Jonas O; Gray JW; Korkola JE
Cell Syst; 2018 Mar; 6(3):329-342.e6. PubMed ID: 29550255
[TBL] [Abstract][Full Text] [Related]
15. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
16. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
[TBL] [Abstract][Full Text] [Related]
17. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
18. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
[TBL] [Abstract][Full Text] [Related]
19. The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.
Majumder A; Sandhu M; Banerji D; Steri V; Olshen A; Moasser MM
Sci Rep; 2021 Apr; 11(1):9091. PubMed ID: 33907275
[TBL] [Abstract][Full Text] [Related]
20. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]